Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (NCT00658814)
A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial is studying the side effects of giving azacitidine together with gemtuzumab ozogamicin to see how well it works in treating older patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Azacitidine may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving azacitidine together with gemtuzumab ozogamicin may kill more cancer cells.
Who can join: Review the eligibility criteria below.
Location: Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
Age range: 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (177 Sites)
Showing the first 25 of 177 sites.
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Stanford Cancer Institute Palo Alto — Palo Alto, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- Smilow Cancer Hospital Care Center at Saint Francis — Hartford, Connecticut
- Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
- OSF Saint Anthony's Health Center — Alton, Illinois
- Decatur Memorial Hospital — Decatur, Illinois
- Heartland Cancer Research NCORP — Decatur, Illinois
- Advocate Sherman Hospital — Elgin, Illinois
- Loyola University Medical Center — Maywood, Illinois
- SSM Health Good Samaritan — Mount Vernon, Illinois
- Springfield Memorial Hospital — Springfield, Illinois
- Franciscan Saint Francis Health-Beech Grove — Beech Grove, Indiana
- Reid Health — Richmond, Indiana
- Hospital District Sixth of Harper County — Anthony, Kansas
- Cancer Center of Kansas - Chanute — Chanute, Kansas
- Cancer Center of Kansas - Dodge City — Dodge City, Kansas
- Cancer Center of Kansas - El Dorado — El Dorado, Kansas
- Cancer Center of Kansas - Fort Scott — Fort Scott, Kansas
- Cancer Center of Kansas-Independence — Independence, Kansas
- Cancer Center of Kansas-Kingman — Kingman, Kansas
- Lawrence Memorial Hospital — Lawrence, Kansas
- Southwest Medical Center — Liberal, Kansas
- Cancer Center of Kansas-Liberal — Liberal, Kansas
- Cancer Center of Kansas - Newton — Newton, Kansas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia
- PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
- Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
- Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
- A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California
Explore by condition: All Acute Myeloid Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.